NewAmsterdam Pharma 8/12/2026 Earnings Report

NewAmsterdam Pharma EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.47
• Beat/Miss: N/A
• One Year Ago EPS: N/A

NewAmsterdam Pharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.88 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NewAmsterdam Pharma Announcement Details

• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

NewAmsterdam Pharma (NASDAQ:NAMSW), Inc. is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials. This candidate is designed to mimic the metabolic benefits of existing GLP-1 injectables— including glucose control and weight reduction—while offering the ease of an oral tablet. In addition, NewAmsterdam Pharma is advancing a pipeline of next-generation oral candidates, including dual agonists that target GLP-1 and other receptors implicated in energy homeostasis. These programs leverage the same foundational chemistry platform to address a broad spectrum of metabolic and inflammatory indications.

Founded in 2020 and headquartered in New York City, NewAmsterdam Pharma has assembled a leadership team with deep expertise in peptide drug development, pharmaceutical formulation and clinical research. The company is supported by a consortium of life science investors and collaborates with academic and industry partners to advance its oral peptide platform. While still in the early phases of clinical evaluation, NewAmsterdam Pharma is positioned to redefine treatment paradigms for chronic metabolic diseases through its innovation in oral peptide therapeutics.